Aorto-iliac occlusive disease (AIOD) is a clinically significant manifestation of systemic atherosclerosis that substantially affects patient quality of life and long-term prognosis. While open surgical revascularization has historically been the primary treatment modality, technological advancements have positioned endovascular therapy (EVT) as the preferred first-line option for most lesions. This review provides a comprehensive overview of the evolution of major international and domestic clinical guidelines, including TASC II, AHA/ACC, ESC, ESVS, and JCS/JSVS, with a focus on the shift from anatomical lesion classification to integrated disease assessment incorporating the WIfI and GLASS classification systems, as well as the increasing importance of personalized medicine. Additionally, we discuss key future perspectives in AIOD management, such as optimal device selection, hybrid revascularization strategies that combine open surgery and EVT, the expanding role of the transradial approach (TRA), optimization of pharmacological therapy (including antiplatelet agents, anticoagulants, and low-dose rivaroxaban combination therapy), and the implementation of shared decision-making (SDM) as a crucial component of contemporary individualized vascular care.
View full abstract